CDC 📈 VictoryShares US EQ Income - Overview
Exchange: NASDAQ • Country: USA • Currency: USD • Type: Etf • ISIN: US92647N8240 • Large Value
CDC: High Dividend Stocks, Large Cap Stocks
The fund seeks to achieve its investment objective by investing, under normal market conditions, at least 80% of its assets directly or indirectly in the securities included in the Nasdaq Victory U.S. Large Cap 100 High Dividend Long/Cash Volatility Weighted Index. The index identifies the 100 highest dividend yielding stocks in the Nasdaq Victory U.S. Large Cap 500 Volatility Weighted Index. ‣ Company URL: http://www.VictorySharesLiterature.com ‣ Domicile: United States
Additional Sources for CDC ETF
News:
Wall Street Journal
Benzinga
Yahoo Finance
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
CDC ETF Overview
| Market Cap in USD | 837m |
| Category | Large Value |
| TER | 0.38% |
| IPO / Inception | 2014-07-01 |
CDC ETF Ratings
| Growth 5y | 52.4% |
| Fundamental | - |
| Dividend | 65.5% |
| Rel. Strength Industry | -13.7 |
| Analysts | - |
| Fair Price Momentum | 62.38 USD |
| Fair Price DCF | - |
CDC Dividends
| Dividend Yield 12m | 3.33% |
| Yield on Cost 5y | 5.00% |
| Annual Growth 5y | 9.96% |
| Payout Consistency | 98.7% |
CDC Growth Ratios
| Growth Correlation 3m | 22.8% |
| Growth Correlation 12m | 95.4% |
| Growth Correlation 5y | 52% |
| CAGR 5y | 8.44% |
| CAGR/Mean DD 5y | 0.99 |
| Sharpe Ratio 12m | 0.89 |
| Alpha | -2.86 |
| Beta | 0.60 |
| Volatility | 22.78% |
| Current Volume | 66.5k |
| Average Volume 20d | 25.4k |
What is the price of CDC stocks?
As of December 22, 2024, the stock is trading at USD 62.45 with a total of 66,475 shares traded.
Over the past week, the price has changed by -2.52%, over one month by -4.46%, over three months by -2.06% and over the past year by +14.84%.
As of December 22, 2024, the stock is trading at USD 62.45 with a total of 66,475 shares traded.
Over the past week, the price has changed by -2.52%, over one month by -4.46%, over three months by -2.06% and over the past year by +14.84%.
Is VictoryShares US EQ Income a good stock to buy?
Partly, yes. Based on ValueRay Analyses, VictoryShares US EQ Income (NASDAQ:CDC) is currently (December 2024) ok to buy, but has to be watched. It has a Growth Technical Rating of 52.43 and therefor an somewhat technical positive rating according to historical growth.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of CDC as of December 2024 is 62.38. This means that CDC is currently overvalued and has a potential downside of -0.11%.
Partly, yes. Based on ValueRay Analyses, VictoryShares US EQ Income (NASDAQ:CDC) is currently (December 2024) ok to buy, but has to be watched. It has a Growth Technical Rating of 52.43 and therefor an somewhat technical positive rating according to historical growth.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of CDC as of December 2024 is 62.38. This means that CDC is currently overvalued and has a potential downside of -0.11%.
Is CDC a buy, sell or hold?
VictoryShares US EQ Income has no consensus analysts rating.
VictoryShares US EQ Income has no consensus analysts rating.
What are the forecast for CDC stock price target?
According to ValueRays Forecast Model, CDC VictoryShares US EQ Income will be worth about 68.5 in December 2025. The stock is currently trading at 62.45. This means that the stock has a potential upside of +9.67%.
According to ValueRays Forecast Model, CDC VictoryShares US EQ Income will be worth about 68.5 in December 2025. The stock is currently trading at 62.45. This means that the stock has a potential upside of +9.67%.
| Issuer | Forecast | Upside |
|---|---|---|
| Wallstreet Target Price | - | - |
| Analysts Target Price | - | - |
| ValueRay Target Price | 68.5 | 9.7% |